

NEXT TECH PATHWAY

Buy today and upgrade to the next technology we release for **\$0.**



The sensor can be worn on the back of the upper arm by those who are ages 14 and up.

LIMITED TIME OFFER TO UPGRADE FOR \$0

AUTOMATIC ENROLLMENT IN THE NEXT TECH PATHWAY PROGRAM

We are working on new technology that could help make it easier to manage your diabetes. Our new program will help you access future innovation.

BUY TODAY

Buy the MiniMed™ 670G system today and you will be automatically enrolled in the Next Tech Pathway program.

UPGRADE DURING YOUR WARRANTY

Following our next technology release, we'll notify you when we are accepting requests for Next Tech Pathway upgrades. If you choose to switch technologies, you'll be able to upgrade at no cost.

ELIGIBILITY

The Next Tech Pathway program is only available to those whose MiniMed™ 670G system shipped starting on 11/7/19. The final day to place an order and be enrolled in the program is 12/1/20. This program is not available to customers on a rental program such as those enrolled in any federal, state, or other government-funded healthcare program like Medicare, Medicare Advantage, Medicaid, Medigap, the Department of Defense ("DoD") or TRICARE.

Medtronic



TERMS AND CONDITIONS

The Next Tech Pathway program (the "Program") allows eligible, enrolled participants whose MiniMed™ 670G system order is shipped starting on 11/7/19 to be included. The last day to place an order is 12/1/20. This Program allows for an upgrade to our next MiniMed™ system at \$0. Eligibility dates subject to change.

To be eligible for the Program, participants must purchase a MiniMed™ 670G system and meet one of the following requirements:

- New to Medtronic insulin pump therapy
- Upgrade from an out-of-warranty pump

To upgrade through the Program, all participants must agree and are subject to these terms and conditions:

- Return of old MiniMed™ 670G insulin pump and transmitter is required. If the old pump and transmitter are not returned within 90 days, you will be charged \$3,200.
- Upon first commercial shipping of a new MiniMed™ system, it may take up to 90 days for Medtronic to contact you with the option to upgrade. Once you place your order, it may take up to 90 days to ship the new product. The Program does not guarantee prioritization of your order.
- An upgrade through the Program can only be redeemed once during your warranty period for the next available technology and customers' order must ship no later than 4/1/21. The Program cannot be redeemed if less than six (6) months remains on your pump warranty.
- Warranty period does not reset when you receive the new technology. The warranty period of an upgraded insulin pump and transmitter will remain the same as the warranty date of the initial pump and transmitter purchased.

For a full list of program terms, please visit our website below.

WANT TO LEARN MORE? VISIT MEDTRONICDIABETES.COM/NEXTTECH



IMPORTANT SAFETY INFORMATION: MINIMED™ 670G SYSTEM

The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR@NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR@NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR@NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the "Always" send mode.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult <http://www.medtronicdiabetes.com/important-safety-information#minimed-670g> and the appropriate user guide at <http://www.medtronicdiabetes.com/download-library>.